X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EB06 is a monoclonal antibody which targets autoreactive T cells that destroy the pigment-producing cells of the epidermis. It binds and inhibits CXCL10 as it is involved in initiation of the disease and the maintenance of vitiligo lesions.
Lead Product(s): EB06
Therapeutic Area: Immunology Product Name: EB06
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
EB05 was developed to regulate the overactive and dysfunctional immune response associated with Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure that accounts for ~10% of all ICU admissions.
Lead Product(s): EB05
Therapeutic Area: Infections and Infectious Diseases Product Name: EB05
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2022
Details:
EB01, is an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor met primary efficacy endpoint, which is the mean percent change from baseline on the CDSI at day 29.
Lead Product(s): EB01
Therapeutic Area: Dermatology Product Name: EB01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JSS Medical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2021
Details:
EB05 is an experimental monoclonal antibody, announced additional results from the Phase 2 part of an ongoing Phase 2/3 clinical study for treatment of hospitalized COVID-19 patients. Additional efficacy signals recorded in a broad range of mild to severe ARDS patients.
Lead Product(s): EB05
Therapeutic Area: Infections and Infectious Diseases Product Name: EB05
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
Positive results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients.
Lead Product(s): EB05
Therapeutic Area: Infections and Infectious Diseases Product Name: EB05
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2021
Details:
EB01 is designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred, the company believes that the drug could potentially exert a powerful anti-inflammatory effect without the safety concerns of steroids.
Lead Product(s): EB01
Therapeutic Area: Dermatology Product Name: EB01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
EB01 contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesa's EB01 topical treatment or a placebo cream.
Lead Product(s): EB01
Therapeutic Area: Dermatology Product Name: EB01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JSS Medical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
Edesa Biotech has received approval from the U.S. FDA and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical trial of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Lead Product(s): EB05
Therapeutic Area: Infections and Infectious Diseases Product Name: EB05
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
EB05 is an experimental monoclonal antibody that Edesa believes could regulate the overactive immune response associated with Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients.
Lead Product(s): EB05
Therapeutic Area: Infections and Infectious Diseases Product Name: EB05
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
EB05 is an experimental monoclonal antibody that the company believes could regulate the overactive immune response associated with Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients.
Lead Product(s): EB05
Therapeutic Area: Infections and Infectious Diseases Product Name: EB05
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
